All News

At the upcoming hearing, the committee will examine the impact of PBMs on access to healthcare and the Pharmacy Benefit Manager Transparency Act which was submitted by Sens. Maria Cantwell and Chuck Grassley.

Sixteen states have banned a pharmacy benefit management practice that involves not counting the value of drug copay assistance from manufacturers toward patient deductibles.

Clarivate analysts have identified the treatments they forecast could deliver annual sales of more than $1 billion within 5 years. These include therapies for rare diseases, as well as HIV, Parkinson’s disease, Crohn’s disease, alopecia, and cancer.